– UK, London – Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, is pleased to announce the appointment of Rolf Hoffmann, as a Non-Executive Director of the Company with immediate effect. Mr Hoffmann is currently Chairman of Biotest AG, sits on the Board of Directors of the large European biotechnology company Genmab AG and is a Director of San Francisco-based Trigemina Inc.
Rolf brings to Shield over 30 years of international pharmaceutical experience having served in several senior roles in the industry, most recently 12 years with Amgen as Senior Vice President of Commercial Operations for the United States, and before that as SVP International and Europe. He started his pharmaceutical career at Eli Lilly as a sales representative, progressing to senior positions including President of Latin America operations and General Manager in Germany. Rolf holds an MBA from the University of North Carolina, a master’s degree from the University of Cologne and is Adjunct Professor at UNC Kenan-Flagler Business School.
Andrew Heath, Chairman of Shield Therapeutics, said: “I am delighted to welcome Rolf to the Board of Shield Therapeutics. His extensive experience and knowledge of the pharmaceutical industry and its key stakeholders in major markets will be helpful in defining the Company’s future strategy and we look forward to Rolf playing a full and active role in these discussions and beyond.”
About Shield Therapeutics plc
Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030’s.
For more information : https://www.shieldtherapeutics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.